BioCryst Pharmaceuticals Inc logo

BioCryst Pharmaceuticals Inc(BCRX)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$7.61
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for BCRX

11/13/2026: BCRX (1-star) is currently NOT-A-BUY. Pass it for now.

BioCryst Pharmaceuticals is a commercial-stage biotechnology company that discovers, develops, and commercializes oral small-molecule medicines for rare diseases. The company's primary strength is the strong commercial adoption of Orladeyo, its flagship oral prophylactic treatment for hereditary angioedema, which provides steady revenue growth. Its core investment story centers on expanding Orladeyo's global footprint and advancing a pipeline of novel complement-targeted therapies. Key risks include revenue concentration on a single main product, intense market competition, and execution hurdles in clinical development. BioCryst suits growth-oriented investors comfortable with biotech sector volatility, who should monitor ongoing quarterly sales trajectories and pipeline clinical milestones.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitBioCryst offers expanding top-line product revenue driven by the market penetration of Orladeyo.
Momentum investorMixed fitMomentum fit is conditional on a positive upturn signal driven by clinical updates or quarterly earnings beats.
Value investorWeak fitThe company prioritizes reinvestment over earnings generation, making traditional value metrics less applicable.
Dividend investorWeak fitBioCryst does not pay dividends, retaining capital for pipeline and commercial expansion.
Low-risk investorWeak fitBiotechnology stocks carry inherent clinical trial, regulatory, and commercial volatility.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighBiotech stock prices frequently fluctuate based on clinical readouts, regulatory decisions, and market sentiment.
Valuation riskMedium / highValuations are heavily dependent on future revenue projections of key growth drivers.
Competition risk (HAE and rare disease market competition)HighMarket share can be challenged by entrenched competitors and emerging alternative therapies.
Business qualityMediumThe transition to a self-sustaining commercial model is anchored by a proven flagship product.
Dividend incomeLow / noneIncome-focused investors will find no dividend yield supporting total return.
Execution riskMedium / highFuture growth relies heavily on successful global commercial expansion and clinical pipeline execution.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.96B USD
Price to earnings Ratio -
1Y Target Price 20.45
Price to earnings Ratio -
1Y Target Price 20.45
Volume (30-day avg) 5.3M shares
Beta 0.51
52 Weeks Range 6.23 - 11.22
Updated Date 11/15/2026
52 Weeks Range 6.23 - 11.22
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -1.28

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Drug Manufacturers - Specialty & Generic

BUY participation
66.7%
Active BUY / eligible
8 / 12
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Downtrend
PRICE PATH

Downtrend

The stock has experienced a sustained decline in price over recent periods.

Moderately Choppy
PRICE STABILITY

Moderately Choppy

The stock has experienced noticeable price swings while retaining some directional structure.

Analysis of Past Performance

Type Stock
Historic Profit -30.49%
Avg. Invested days 27
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
BCRX receives a 4-star rating, supported by strong unit economics, strong company fundamentals, and solid analyst coverage. The rating is constrained by weak price momentum.

Company Fundamentals

★★★★★
BCRX has strong overall fundamentals (5 stars), with solid financial health, strong growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+396.9%) and strong cash generation (FCF margin 37.4%) are partially offset by modest insider ownership of 3.35%.

Financial Health Rating

★★★★★
BCRX's financial health is supported by strong liquidity, including working-capital and asset support (WC/assets 40.5%). Operating efficiency is solid (4 stars), which helps explain the 4-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is BCRX's strongest growth driver at +716.1% FY2025 versus FY2024 (strong, 5 stars). Revenue growth (+94.1%, strong) and earnings growth (+396.9%, strong) are also constructive, though not equally high across every growth measure.

Ownership

★★★★★
Institutional ownership is 106.0% and approximately 87.1% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 3.35% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 9.29%
RA Capital Management, LLC 6.15%
State Street Corp 5.90%
Deerfield Management Co 5.87%
Vanguard Capital Management, LLC 4.42%

Unit Economics (Per $1K Revenue)

★★★★★
BCRX generates approximately $978 of gross profit, $390 of operating income, and $374 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Strong margins, cash conversion, and capital efficiency support the rating.

Economic Dimensions

★★★★★
Effective Tax Rate: 1.32%

Quantitative Style Profile

★★★★★
BCRX has a high-quality, liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Quality TiltLow VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Product Sales (Orladeyo)Global net sales of Orladeyo for the prophylactic treatment of hereditary angioedema attacks.This is the primary engine driving the company's financial results and commercial validation.
Product Sales (Rapivab)Hospital and institutional sales of Rapivab for acute influenza treatment.Provides supplementary seasonal revenue streams.
Partnering and License RevenuesUpfront fees, milestone payments, and royalties from collaborative development agreements.Offers non-dilutive capital injections derived from technological partnerships.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date 2026-11-04
When Before Market
Estimate 0.1
Actual 0.14

Profitability

Profit Margin -37.41%
Operating Margin (TTM) 48.75%

Management Effectiveness

Return on Assets (TTM) 56.48%
Return on Equity (TTM) -1925.37%

Valuation

Trailing PE -
Forward PE 12.9
Enterprise Value 2.37B
Price to Sales(TTM) 2.04
Enterprise Value 2.37B
Price to Sales(TTM) 2.04
Enterprise Value to Revenue 2.46
Enterprise Value to EBITDA 31.24
Shares Outstanding 257.30M
Shares Floating 224.08M
Shares Outstanding 257.30M
Shares Floating 224.08M
Percent Insiders 3.35
Percent Institutions 106.03

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.